【摘要】 地诺孕素(Dienogest, DNG)作为一种高效孕激素，其良好的安全性和耐受性在大量的临床实践中被广泛证实，逐渐成为治疗子宫内膜异位症的一线用药，但是在长期使用过程中，仍然会有一些不良事件的发生，如骨密度降低、乳房不适、不规则出血、情绪低落及体重增加等，但其总体发生率低。目前临床上相关证据有限，就用药期间是否能引起骨密度降低以及与乳腺癌的相关关系等还需要进一步研究证实，然而，这些不良事件的发生在一定程度上影响了患者的生活质量。长期治疗过程中，应密切随访患者的用药情况及情绪变化等，及时给予相应的干预措施以减少不良事件的发生，从而在一定程度上改善患者的生活质量。更多还原

【Abstract】 Dienogest(DNG),as a highly efficient progesterone, whose safety and tolerability has been widely confirmed in a large number of clinical practices, has gradually become the first-line drug in the treatment of endometriosis.However, some adverse events still occur in the long-term use of DNG,such as reduced bone mineral density, breast discomfort, irregular bleeding, depression and weight gain, but the overall incidence is low.At present, the relevant clinical evidence is limited, and further studies are needed to confirm whether the drug can cause bone mineral density reduction and its correlation with breast cancer.However, the occurrence of these adverse events affects the quality of life of patients to some extent.In the long-term treatment process, we need to closely follow up patients′ medication status and emotional changes, and give corresponding intervention measures in time to reduce the occurrence of adverse events and improve patients′ quality of life to a certain extent.更多还原